Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

cribed and for those who are not opioid tolerant.
  • Patients and their caregivers must be instructed that Lazanda contains medicine in an amount that could be fatal to a child and thus must keep both used and unused bottles in their child-resistant container and out of the reach of children at all times and all residual fentanyl must be emptied before disposal.
  • Patients on concomitant CNS depressants must be monitored for a change in opioid effects and adjust the dose of Lazanda.
  • Concomitant use with potent cytochrome P450 3A4 inhibitors may increase depressant effects including hypoventilation, hypotension, and profound sedation. Monitor and consider dosage adjustment if warranted.
  • Cautiously adjust the dose of Lazanda in patients with chronic obstructive pulmonary disease or preexisting medical conditions predisposing them to respiratory depression.
  • Administer Lazanda with extreme caution in patients particularly susceptible to intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure or impaired consciousness.
  • Patients taking Lazanda must be warned that opioid analgesics impair the mental and/or physical ability required for the performance of potentially dangerous tasks (e.g., driving a car or operating machinery).
  • Use Lazanda with caution in patients with bradyarrhythmias.
  • Lazanda is not recommended for use in patients who have received MAO inhibitors within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.

  • Drug Interactions

  • Potential interactions may occur when Lazanda is given concurrently with agents that affect CYP3A4 activity.  Monitor patients for signs of opioid toxicity who begin therapy with, or increase the dose of, inhibitors of CYP3A4 or stop therapy with, or decrease the dose of, inducers of CYP3A4. Monitor patients who are taking vasoconstric
    '/>"/>

  • SOURCE Archimedes Pharma Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
    2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
    3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
    4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
    5. Novo Nordisk A/S: PharmaVitae Profile
    6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
    7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
    8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
    9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
    10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
    11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
    (Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
    (Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
    Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, ... Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro ... The award gives Bacterin ,pre-approved, ready-access to ...
    ... PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 ... announced a collaboration for the process development and cGMP ... used in Phase I and Phase II clinical trials. ... is prostatectomy, or removal of the prostate," noted David ...
    Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Goodwin Biotechnology Announces a Collaboration with Spectros Corporation 2
    (Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
    (Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
    (Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
    Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
    ... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce results ... During a conference call on October 25 at 10:30 ... will,address inquiries from investors and analysts. Investors and ... live,webcast of the call at http://www.bms.com/ir or ...
    ... increase the risk of bleeding from the stomach, according ... , The antidepressant drugs, selective serotonin reuptake inhibitors known ... Clinical Excellence (NICE). SSRIs are very widely used in ... last year, probably to about 1.5 million patients. , ...
    ... to Launch Medi-Scripts PLUS - Prescription Pads with ... ... Medi-Promotions, Inc.,the originator of Medi-Scripts(R) prescription pads, today announced that,it ... company,s next generation prescription pad model. Being launched this,month at ...
    ... Health Management Systems,Inc. (HMS) today announced that ... Inc. d/b/a/ Permedion, an independent health care quality ... this,acquisition, HMS augments its portfolio of program integrity ... agencies and,managed care organizations. Permedion utilizes advanced ...
    ... 8 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... company that develops, manufactures and markets advanced in-,vitro ... systems, today announced that it has posted its ... http://ir.chinameditech.com . The 2006,annual report includes ...
    ... treatment for breast cancer differs between African-American women and ... insurance type. The study appears in the November 15, ... American Cancer Society. , Dr. Mousumi Banerjee of ... from Wayne State University and Dr. William Hryniuk from ...
    Cached Medicine News:Health News:Antidepressants and painkillers - a dangerous combination 2Health News:Medi-Promotions Hires Industry Executive to Expand its Medi-Scripts Prescription Pad Model 2Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:China Medical Technologies to Post 2006 Annual Report on Its Website 2Health News:Differences observed between black and white women in use of breast cancer therapy 2
    ... Cytometry Concentrate is for use as a ... cytometry. Each 70ml bottle of Cytometry Concentrate ... distilled water. Compared to Cubitainers, Streck Cytometry ... and saves money without compromising performance. Streck ...
    ... CD34 is a stabilized preparation ... can be used as a ... CD34 positive cells. It is ... ProCOUNT gating strategies. CD-Chex CD34 ...
    ... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
    Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
    Medicine Products: